CN114929683B - 作为钙激活氯化物通道调节剂的吡啶衍生物 - Google Patents

作为钙激活氯化物通道调节剂的吡啶衍生物 Download PDF

Info

Publication number
CN114929683B
CN114929683B CN202080053457.2A CN202080053457A CN114929683B CN 114929683 B CN114929683 B CN 114929683B CN 202080053457 A CN202080053457 A CN 202080053457A CN 114929683 B CN114929683 B CN 114929683B
Authority
CN
China
Prior art keywords
compound
amino
pyridine
acetyl
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080053457.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN114929683A (zh
Inventor
S·科林伍德
C·巴克斯顿
M·哈伯古德
J·D·哈格瑞夫
T·B·施菲尔德
M·史密斯
C·史汀生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transmembrane Protein 16a Ltd
Original Assignee
Transmembrane Protein 16a Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transmembrane Protein 16a Ltd filed Critical Transmembrane Protein 16a Ltd
Publication of CN114929683A publication Critical patent/CN114929683A/zh
Application granted granted Critical
Publication of CN114929683B publication Critical patent/CN114929683B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080053457.2A 2019-07-24 2020-07-24 作为钙激活氯化物通道调节剂的吡啶衍生物 Active CN114929683B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1910608.7 2019-07-24
GBGB1910608.7A GB201910608D0 (en) 2019-07-24 2019-07-24 Compounds
PCT/GB2020/051785 WO2021014172A1 (en) 2019-07-24 2020-07-24 Pyridine derivatives as calcium-activated chloride channel modulators

Publications (2)

Publication Number Publication Date
CN114929683A CN114929683A (zh) 2022-08-19
CN114929683B true CN114929683B (zh) 2024-09-03

Family

ID=67839705

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080053457.2A Active CN114929683B (zh) 2019-07-24 2020-07-24 作为钙激活氯化物通道调节剂的吡啶衍生物

Country Status (6)

Country Link
US (1) US12545658B2 (https=)
EP (1) EP4003977B1 (https=)
JP (1) JP7682850B2 (https=)
CN (1) CN114929683B (https=)
GB (1) GB201910608D0 (https=)
WO (1) WO2021014172A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145726A1 (en) * 2018-01-26 2019-08-01 Enterprise Therapeutics Limited Compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) * 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
US6262040B1 (en) * 1996-09-04 2001-07-17 Pfizer Inc Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
CA2419224A1 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US7642277B2 (en) * 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US9550737B2 (en) * 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
US9458124B2 (en) * 2013-02-06 2016-10-04 Wayne State University Substituted pyran derivatives
AU2016247768B2 (en) * 2015-04-17 2019-03-07 Corteva Agriscience Llc Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
HUE064145T2 (hu) * 2016-04-15 2024-03-28 Epizyme Inc Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok
GB201610854D0 (en) * 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
AU2018211529A1 (en) * 2017-01-27 2019-08-29 Genfit N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxa zin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases
US11358947B2 (en) * 2017-04-17 2022-06-14 The Regents Of The University Of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145726A1 (en) * 2018-01-26 2019-08-01 Enterprise Therapeutics Limited Compounds

Also Published As

Publication number Publication date
CN114929683A (zh) 2022-08-19
US20220144803A1 (en) 2022-05-12
EP4003977B1 (en) 2026-04-15
JP7682850B2 (ja) 2025-05-26
EP4003977A1 (en) 2022-06-01
WO2021014172A1 (en) 2021-01-28
GB201910608D0 (en) 2019-09-04
US12545658B2 (en) 2026-02-10
JP2022541638A (ja) 2022-09-26

Similar Documents

Publication Publication Date Title
US12377105B2 (en) Compounds
US12415793B2 (en) Modulators of TMEM16A for treating respiratory disease
US20200361871A1 (en) Compounds
US12552770B2 (en) Compounds for treating respiratory disease
US20220235006A1 (en) Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions
CN114929683B (zh) 作为钙激活氯化物通道调节剂的吡啶衍生物
HK40075169A (en) Pyridine derivatives as calcium-activated chloride channel modulators
HK40075169B (zh) 作为钙激活氯化物通道调节剂的吡啶衍生物
HK40067765A (en) Modulators of tmem16a for treating respiratory disease
TW202237090A (zh) 治療呼吸道疾病之化合物
HK40067764A (en) Compounds for treating respiratory disease
WO2021014169A1 (en) Crystalline form of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-cyclohexyl-pyridine-2-carboxamide
HK40067765B (zh) 用於治疗呼吸系统疾病的tmem16a的调节剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40075169

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant